Lv11
20 积分 2023-10-31 加入
Axial spondyloarthritis
3小时前
待确认
Goodbye to the term ‘ankylosing spondylitis’, hello ‘axial spondyloarthritis’: time to embrace the ASAS-defined nomenclature
3小时前
已完结
Molecular Mechanisms Regulating Matrix Metalloproteinases
8个月前
已完结
Matrix metalloproteinases in arthritis: towards precision medicine
9个月前
已完结
Patient-tailored dose reduction of tumor necrosis factor inhibitors in axial spondyloarthritis
1年前
已完结
Treatment of axial spondyloarthritis: an update
1年前
已完结
Australian recommendations on tapering of biologic and targeted synthetic disease‐modifying anti‐rheumatic drugs in inflammatory arthritis
1年前
已完结
Response to: Correspondence on "ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update" by Ramiroet al
1年前
已完结
Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis
1年前
已完结
Disease Activity-Guided Stepwise Tapering but Not Discontinuation of Biologics Is a Feasible Therapeutic Strategy for Patients with Ankylosing Spondylitis: Real-World Evidence
1年前
已完结
皖公网安备34019202002308
